Does statin therapy stabilize plaque?
Best insight from top research papers
Statin therapy has been shown to stabilize and even reduce atherosclerotic plaque burden in coronary circulation . Meta-analyses of clinical trials have reported a significant reduction in plaque volume and percent atheroma volume with statin treatment . High-intensity statin therapy has been found to decrease plaque burden and gadolinium uptake, indicating plaque stabilization . Additionally, combined treatment with statins and omega-3 supplements has been shown to further delay plaque progression, increase fibrous cap thickness, and reduce plasma high-sensitivity C-reactive protein levels . Serial imaging studies using optical coherence tomography and intravascular ultrasound have demonstrated that statin therapy, whether with atorvastatin or rosuvastatin, can effectively stabilize lipid-rich plaques . Overall, the evidence suggests that statin therapy plays a crucial role in stabilizing and regressing coronary artery plaques.
Answers from top 4 papers
More filters
| Papers (4) | Insight |
|---|---|
2 Citations | Yes, statin therapy plays an important role in stabilizing and regressing coronary artery plaques. (Answer is in the paper) |
| The paper provides evidence that high-intensity statin therapy can lead to a decrease in plaque burden, area degree of stenosis, and gadolinium uptake, suggesting that statin therapy may stabilize plaque. | |
| The paper states that statin therapy is beneficial for plaque regression, suggesting that it may stabilize and reverse atherosclerotic plaque. | |
| Yes, statin therapy has been shown to stabilize and even reduce the burden of coronary atherosclerosis, according to the paper. |
Related Questions
How effective is red rice in stabilizing athreosclerotic plaque?4 answersRed yeast rice (RYR) has been shown to be effective in stabilizing atherosclerotic plaque. Studies have demonstrated that RYR treatment can improve plaque stability without decreasing plaque area. RYR has also been found to reduce the protein levels of matrix metalloproteinase-9 (MMP-9) and nuclear factor κB (NF-κB) in the aorta, indicating its ability to stabilize unstable plaques. Additionally, RYR treatment has been shown to mitigate macrophage endoplasmic reticulum (ER) stress, inhibit apoptosis, and suppress the NF-κB pro-inflammatory pathway, all of which contribute to plaque stability. These findings suggest that RYR can effectively suppress vulnerable plaque progression and rupture, providing a potential therapeutic strategy for stabilizing atherosclerotic plaques.
How to maintain oral health?5 answersTo maintain oral health, it is important to follow proper oral hygiene practices such as regular brushing and flossing. Additionally, a healthy diet and lifestyle are crucial for oral health maintenance. Ayurveda recommends specific procedures like dantdhavan, jihvanirlekhan, pratisaran, gandoosha, and the use of single drugs decoction as mouth rinse for maintaining a healthy oral cavity. Good communication between dental professionals and families is essential, especially for children, to emphasize the importance of diet control, oral hygiene, and individualized recall dental visits. Machine learning techniques can be used to identify potential oral pathologies and facilitate oral health maintenance. Children with chronic respiratory diseases may have higher prevalence of oral diseases, so preventive measures, early diagnosis, and effective treatment strategies are important. Finally, an oral-health composition that promotes self-activation and continuous production of reactive oxygen can be used for maintaining oral health.
Chemokines and atherosclerotic plaque progression: towards therapeutic targeting?4 answersChemokines play a crucial role in the initiation, progression, and destabilization of atherosclerotic plaques. They mediate the recruitment of leukocytes, which is characteristic of atherothrombosis. Several chemokines have been associated with plaque destabilization and rupture, making them potential biomarkers and therapeutic targets. Recent developments have shed light on the regulation of chemokine expression and function in atherosclerosis, including the identification of components that regulate the proatherogenic chemokine CCL5. Chemokines and their receptors have been targeted in preclinical studies using various approaches, such as competitive ligands and microRNAs, showing promising results in ameliorating atherosclerosis. Inhibition of multiple chemokine axes and targeting heterophilic interactions of chemokines are potential strategies for treating atherosclerosis. Overall, chemokines present attractive yet complex therapeutic targets for the prevention and treatment of atherosclerosis.
What are the long-term effects of lipid lowering on atherosclerosis and plaque?5 answersLipid lowering therapy has been shown to have long-term effects on atherosclerosis and plaque. Randomized clinical trials have demonstrated that intensive lipid lowering reduces the rate of cardiovascular events and promotes plaque regression and stabilization. The benefit of statins, the mainstay of lipid lowering therapy, is mainly mediated by the lowering of LDL cholesterol (LDL-C). Studies employing intracoronary imaging have shown that pharmacological treatment can slow disease progression or promote plaque regression, depending on the degree of lipid lowering achieved. Statins have been shown to reduce lipid content and stabilize atherosclerotic plaque with thickened fibrous caps and macrocalcification. In patients with homozygous familial hypercholesterolaemia, LDL-receptor-independent agents have demonstrated remarkable improvement in LDL-C levels, disappearance of xanthomatosis, and regression in atherosclerotic plaques. These findings highlight the efficacy of lipid lowering therapy in reducing atherosclerosis and stabilizing plaque, thereby reducing the risk of cardiovascular events.
What REDUCES arterial plaque build up?5 answersReducing arterial plaque buildup can be achieved through various approaches. One method is the use of a novel non-depleting blocking anti-IL-1RAP antibody, which has been shown to reduce plaque burden and inflammation in atherosclerotic mice. Another approach involves disrupting IL-1RAP signaling using this antibody, which has been found to limit plaque inflammation. Additionally, inhibiting the NLRP3 inflammatory pathway with tacrolimus has been shown to reduce the formation of atherosclerotic plaques. Furthermore, the dystrophin-glycoprotein complex and β-sarcoglycan have been found to affect the atherosclerotic process, and their deficiency can lead to a reduction in plaque development. Finally, low shear stress has been identified as a contributor to inflammatory diseases such as atherosclerosis, and modulating the Notch signaling system has shown potential in reducing LSS-induced inflammation response during atherosclerosis.
What is the atherosclerotic plaque composed of?3 answersAtherosclerotic plaque is composed of a mixture of elements including lipoproteins, cholesterol, extracellular matrix proteins, and various types of immune and non-immune cells. The plaque also contains lipids, oxidized lipids, and lipid-loaded macrophages and smooth muscle cells, which form foam cells. The plaque's composition also includes modified lipoprotein particles, vascular cells, and leukocytes. Additionally, the plaque contains apatite crystals, fibrous-like cholesterol, and amorphous organic material, with hydroxyapatite being the most abundant mineral. Proteoglycans, triglycerides, cholesterol, cholesterolester, and crystalline calcium are also present in atherosclerotic plaques.